Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

NCT02306161 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02306161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02306161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 12, 2014
Completion date
September 16, 2027
Enrollment
312 (actual)
Sites
314

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic ewing sarcoma, metastatic malignant neoplasm in the bone, metastatic malignant neoplasm in the bone marrow, metastatic malignant neoplasm in the lung, metastatic peripheral primitive neuroectodermal tumor of bone, peripheral primitive neuroectodermal tumor of soft tissues